Clinical Trial Evaluating COVID-19 Variant Vaccine Begins,

On February 24, the biotechnology company Moderna Therapeutics announced that it had shipped its variant-specific COVID-19 vaccine candidate, mRNA-1273.351, to the National Institutes of Health (NIH) …, On February 24, the biotechnology company Moderna Therapeutics announced that it had shipped its variant-specific COVID-19 vaccine candidate, mRNA-1273.351, to the National Institutes of Health (NIH) …, Read More

Scroll to Top